PrimeVax Immuno-Oncology Inc. is developing a multi-mechanism treatment for cancer, leveraging whole body systemic fever along with personalized neo-antigens. Our therapeutic design is to be the only one-time, one-week cancer treatment.
We combine dengue fever virus and autologous dendritic cells to induce a strong immune response along with personalized tumor targeting. We focus on cancer cells resistant to prior treatments.
Our design philosophy is fundamentally different than current cancer development trends. We intend to induce a controlled fever and initiate a strong immune response in one week while the patient is fully under homeostatic control. The immune changes induced by our therapy have synergy potential with checkpoint inhibitors and other standard of care therapies.